Gain Therapeutics shares fall 2.17% premarket after Biogen and Stoke Therapeutics present new clinical data.

Gain Therapeutics, Inc. declined 2.17% in premarket trading. The recent news events do not directly relate to Gain Therapeutics, Inc. but rather to Stoke Therapeutics, Inc. and Biogen Inc. The news events highlight positive clinical data from studies of zorevunersen, an investigational antisense oligonucleotide for the treatment of Dravet syndrome. This news is bullish for Stoke Therapeutics, Inc. and Biogen Inc., but does not explain the decline in Gain Therapeutics, Inc. stock price.